New Vitamin D paper

expand_more

315K views1 month ago

thumb_upLike

thumb_downDislike

library_addSave

flagReport

Dr. John Campbell check_circle

2K subscribers

Vitamin D: A key player in COVID‐19 immunity and lessons from the pandemic to combat immune‐evasive variants https://link.springer.com/article/10.1007/s10787-024-01578-w As of July 2024 775,754,322 confirmed cases of COVID-19 13,578,710,228 vaccine doses had been administered It is unclear why some patients develop severe symptoms while others do not, literature suggests a role for vitamin D. Vitamin D plays a crucial role in the infection or in ameliorating the severity of symptoms. VDD is associated with increased hospitalization of severely ill patients and increased levels of COVID-19-caused mortality. The mechanism of action of vitamin D and vitamin D deficiency (VDD) is well understood. Vitamin D levels and genetic variations in the vitamin D receptor (VDR) gene significantly impact the severity and out- comes of COVID-19, especially in the infections caused by Delta and Omicron variants. Furthermore, VDD causes immune system dysregulation upon infection with SARS-CoV-2, indicating that vitamin D sufficiency is crucial in fighting against COVID-19 infection. Potential role as a prophylactic and treatment adjunct. Immunomodulatory and anti-inflammatory effects of vitamin D Ability to enhance the efficacy of new antiviral drugs Large- scale randomized trials are required to reach a definitive conclusion. Mechanisms of action Macrophages activated to produce defensive proteins and stimulate naïve T cells Activate T lymphocytes and mature B lymphocytes into plasma cells Prevents inflammation, vasoconstriction, and fibrosis of the lungs. Prevents excess release of cytokines from macrophages Prevents excessive CRP production in the liver Vit D can reduce viral replication Vitamin D can protect against ARDS, the main death-causing complication of COVID-19 Seven out of nine studies reviewed by Yisak https://pubmed.ncbi.nlm.nih.gov/33447107/ have indicated a crucial role in vitamin D status in COVID-19 infection, prognosis, and mortality. Vitamin D dose To decrease the risk of contracting a new infection, people at high risk of COVID-19 to take 10,000 IU d−1 of vitamin D for a few weeks, followed by 5000 IU d−1 to raise the concentrations of the active form of vitamin D. Blood levels Levels below 12 ng/mL indicate severe deficiency. Levels between 12 and 20 ng/mL suggest deficiency Treatment recommended for levels below 30 ng/mL Optimal levels are 30–60 ng/mL, Recommended prophylactic dose 0–1 years, 400 IU/day (10 mcg) over 1 year, 600 IU (15 mcg) over 8 years, half an adult dose Adults, 800– 2000 IU of cholecalciferol Routine toxicity monitoring is unnecessary for doses under 10,000 IU/day

physiology,nursing,NCLEX,health,disease,biology,medicine,nurse education,medical education,pathophysiology,campbell,human biology,human body,ENuGXJB06o0,, Health,Society, channel_UCF9IOB2TExg3QIBupFtBDxg, video_ENuGXJB06o0

vid:239657

Comments0

unfold_more

00:05:15

Politicians for the people

more_vert

Dr. John Campbell check_circle

29K views 3 days ago

,Mr. Russell Broadbent, MP https://russellbroadbent.com.au Letter to Anthony Albanese, Australian Prime Minister https://russellbroadbent.com.au/australiansdemandanswers/ Mr Broadbent on X, https://twitter.com/BroadbentMP Great discussion with Mr. Russell Broadbent MP. A politician who advocates for and correctly represents his constituents and the wider world. Thank you. … our fathers brought forth on this continent, a new nation, conceived in Liberty, and dedicated to the proposition that all men are created equal. … and that government of the people, by the people, for the people, shall not perish from the earth. Abraham Lincoln November 19, 1863 The Hon Anthony Albanese MP Prime Minister Parliament House CANBERRA ACT 2600 By email: parliament@pm.gov.au Dear Prime Minister I refer to my letter of 20 September 2024 calling on the government to immediately suspend the use of Pfizer and Moderna Covid-19 products due to the evidence of significant synthetic DNA contamination, as detailed in Dr. David Speicher’s report. Unlike the Thalidomide tragedy, which resulted in over 10,000 victims globally, the Covid-19 vaccines have been administered to more than 20 million Australians, totalling over 63 million doses. The contamination detected in these vaccines, if not addressed, presents a substantial risk, with the potential for these dangers - such as genomic integration and potential long-term health impacts - to multiply with each additional dose administered. Immediate action through a suspension of these products is critical to mitigate further risk. To assist in adopting a precautionary approach and minimizing further harm, I enclose a Science Summary created and endorsed by eminent Australian and international scientists and medical experts. The summary reinforces the known and potential dangers of DNA contamination and highlights the need for an urgent and independent investigation. As advised by the co-signatories, the Department of Health and Aged Care has produced no evidence to demonstrate why the detected DNA contamination will not produce the dire adverse health outcomes detailed in the Science Summary. Additionally, I have reason to believe that multiple attempts by prominent scientists to warn the TGA of these risks have been disregarded since early 2021, raising serious questions about the agency's ability to protect the health and well-being of Australians. Finally, I draw your attention to the Biosecurity Act 2015, which may now be relevant. Given the contamination evidence, I recommend the Minister for Agriculture initiate a Biosecurity Import Risk Analysis of these products, potentially leading to the suspension of these products due to the risks they pose to human health. I gratefully acknowledge the assistance of the 52 co-signatories below in the preparation of this letter and reiterate my call seeking your urgent action to ensure the safety of all Australians. Yours sincerely Russell Broadbent MP Member for Monash

00:17:25

more_vert

Dr. John Campbell check_circle

102K views 3 weeks ago

00:17:42

New mRNA vaccine trials

more_vert

Dr. John Campbell check_circle

133K views 1 month ago

,Intradermal Mycobacterium vaccae and obuense (IMM-101) Oral Non-typeable Haemophilus influenzae (NTHi) UK could be first country to offer norovirus jab against ‘winter vomiting bug’ New vaccine could stop people developing the highly infectious illness after early trial results found it creates a ‘strong immune response’ https://www.telegraph.co.uk/news/2024/10/23/norovirus-vaccine-winter-vomiting-bug-moderna-wes-streeting/ mRNA Systemic distribution inevitable Antigenic dose produced varies Longevity of mRNA? Use of synthetic base Contamination from manufacturing process https://www.nihr.ac.uk/news/uks-first-norovirus-mrna-vaccine-trial-launched First Phase 3 randomised clinical trial Nova 301 trial, mRNA-1403 Trivalent, targeting three major strains of norovirus mRNA norovirus vaccine, UK wide, 39 sites Sponsored by Moderna, Trial evaluates the efficacy and safety of mRNA-1403 Aims to recruit 2,500 participants, UK, late October to early 2025 Some mobile sites for community visits 25,000 globally Half mRNA, half placebo 18 years + but 60 + wanted Single dose vaccine at the first visit - a jab given in the upper arm. The trial lasts up to 25 months. At least six in-person visits to the clinical trial site, and five phone calls with the trial team. Part of a 10-year partnership between Moderna and the UK Health Security Agency (UKHSA) on behalf of UK Government https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research UK Vaccine Innovation Pathway (VIP) and the NIHR working together to accelerate vaccine trials in the UK. https://bepartofresearch.nihr.ac.uk/?utm_source=nihr-website&utm_medium=referral&utm_campaign=bpor-nova Dr Patrick Moore, Chief Investigator of the trial The UK is really pleased to be able to play an important role in helping find an effective vaccine against this highly contagious disease. NIHR Chief Executive Professor Lucy Chappell Leveraging the UK’s expertise in vaccine development, the DHSC through the NIHR and Moderna are delivering this large-scale trial at pace, so that people across the UK and the world can benefit sooner. From the NIHR site the Nova 301 trial serves as a model for future collaborations between the public and private sectors in advancing medical research. Norovirus https://www.cdc.gov/norovirus/data-research/index.html#:~:text=Economic%20impact,-Norovirus%20illness%20is&text=Every%20year%2C%20norovirus%20is%20estimated,healthcare%20costs%20and%20lost%20productivity. https://emedicine.medscape.com/article/224225-overview Worldwide, about 1 out of every 5 cases of acute gastroenteritis is caused by norovirus. Gastroenteritis typically develops 12-48 hours after ingestion of contaminated food or water or after contact with an infected individual. Symptoms typically last for 24-72 hours. All ages Nausea and vomiting Watery diarrhea Possible dehydration Abdominal cramps Headaches Low-grade fever Myalgias and malaise Norovirus genus More than 40 different strains GII.4 Sydney Transmission Person to person, direct contact, exposure to aerosols, fecal–oral routes. ID50 = 10 virions

00:25:35

Functional mushrooms

more_vert

Dr. John Campbell check_circle

1 views 4 months ago

keyboard_arrow_left

Tim Pool

Alex Jones Show

Bannons War Room

Trump

navigate_next

Dr. John Campbell check_circle

315K views 1 month ago

,Vitamin D: A key player in COVID‐19 immunity and lessons from the pandemic to combat immune‐evasive variants https://link.springer.com/article/10.1007/s10787-024-01578-w As of July 2024 775,754,322 confirmed cases of COVID-19 13,578,710,228 vaccine doses had been administered It is unclear why some patients develop severe symptoms while others do not, literature suggests a role for vitamin D. Vitamin D plays a crucial role in the infection or in ameliorating the severity of symptoms. VDD is associated with increased hospitalization of severely ill patients and increased levels of COVID-19-caused mortality. The mechanism of action of vitamin D and vitamin D deficiency (VDD) is well understood. Vitamin D levels and genetic variations in the vitamin D receptor (VDR) gene significantly impact the severity and out- comes of COVID-19, especially in the infections caused by Delta and Omicron variants. Furthermore, VDD causes immune system dysregulation upon infection with SARS-CoV-2, indicating that vitamin D sufficiency is crucial in fighting against COVID-19 infection. Potential role as a prophylactic and treatment adjunct. Immunomodulatory and anti-inflammatory effects of vitamin D Ability to enhance the efficacy of new antiviral drugs Large- scale randomized trials are required to reach a definitive conclusion. Mechanisms of action Macrophages activated to produce defensive proteins and stimulate naïve T cells Activate T lymphocytes and mature B lymphocytes into plasma cells Prevents inflammation, vasoconstriction, and fibrosis of the lungs. Prevents excess release of cytokines from macrophages Prevents excessive CRP production in the liver Vit D can reduce viral replication Vitamin D can protect against ARDS, the main death-causing complication of COVID-19 Seven out of nine studies reviewed by Yisak https://pubmed.ncbi.nlm.nih.gov/33447107/ have indicated a crucial role in vitamin D status in COVID-19 infection, prognosis, and mortality. Vitamin D dose To decrease the risk of contracting a new infection, people at high risk of COVID-19 to take 10,000 IU d−1 of vitamin D for a few weeks, followed by 5000 IU d−1 to raise the concentrations of the active form of vitamin D. Blood levels Levels below 12 ng/mL indicate severe deficiency. Levels between 12 and 20 ng/mL suggest deficiency Treatment recommended for levels below 30 ng/mL Optimal levels are 30–60 ng/mL, Recommended prophylactic dose 0–1 years, 400 IU/day (10 mcg) over 1 year, 600 IU (15 mcg) over 8 years, half an adult dose Adults, 800– 2000 IU of cholecalciferol Routine toxicity monitoring is unnecessary for doses under 10,000 IU/day